To overcome physician resistance to new technology, the tool integrates as a seamless add-on to existing ambient listening scribe software. This passive screening approach requires no change in clinical workflow, no extra clicks, and no new habits, making adoption frictionless for time-constrained clinicians.
The diagnostic tool intentionally disregards the content of speech (what is said), which can be misleading. Instead, it analyzes objective vocal biomarkers—like pitch and vocal cord vibration—to detect disease, as these physiological signals are much harder to consciously alter, bypassing patient subjectivity.
While positioned as a clinical decision support tool rather than a formal diagnostic, the technology is still reimbursable under existing CPT codes. This provides a direct financial incentive for providers, a critical advantage in a healthcare system where new, unreimbursed technologies face steep adoption hurdles.
The system uses "diarization" to distinguish between patient and physician voices, focusing analysis only on the patient. However, the company has the capability to analyze clinician speech to detect signs of burnout or stress. While currently turned off, this represents a significant future application for improving provider well-being.
The vocal biomarker platform provides accurate clinical decision support on the very first encounter with a patient. It doesn't require a personal baseline because its models are pre-trained on large datasets of both healthy individuals and those with specific conditions, making it immediately useful in any clinical setting.